2591’s safety profile is very good, and with the indications we are targeting I believe you only need to show moderate improvements in the efficacy for the FDA to approve. As long as its safe to use.
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-46
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.000(0.00%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.97 | $19.69 | $4.156M | 209.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 246 | $19.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 512 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |